Celltrion is a global biopharmaceutical company founded in 2002 and headquartered in Incheon, South Korea. The company specializes in the development, manufacturing, and commercialization of biosimilars, with its product portfolio approved in approximately 100 countries worldwide. Its therapeutic focus spans immunology, oncology, hematology, ophthalmology, and endocrinology.
The company's core technical expertise encompasses the full biopharmaceutical value chain, including monoclonal antibody development, clinical trials, regulatory affairs, and large-scale manufacturing. Celltrion operates with an annual production capacity of 250,000 liters and reports a production success rate of over 99%. The firm consistently allocates approximately 20% of its annual revenue to research and development.
Celltrion is a significant player in the biosimilars industry, a field it has been involved in pioneering since its founding. The company's operations are structured to provide comprehensive solutions from initial R&D through to the final distribution of its biologic medicines.
